Related Experiment Video
Updated: Oct 1, 2025
A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome
Published on: May 22, 2019
Selective Xi reactivation and alternative methods to restore MECP2 function in Rett syndrome
Niklas-Benedikt Grimm1, Jeannie T Lee2
1Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA; Department of Genetics, The Blavatnik Institute, Harvard Medical School, Boston, MA, USA; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Selective X-chromosome reactivation offers a potential cure for females with X-linked neurodevelopmental disorders like Rett syndrome. This approach aims to utilize the healthy gene copy on the inactive X chromosome within affected cells.
Area of Science:
- Genetics
- Neurodevelopmental Disorders
- Molecular Biology
Background:
- The X-chromosome contains a disproportionately high number of genes linked to intellectual disability.
- X-linked neurodevelopmental disorders disproportionately affect males due to their single X chromosome.
- Females can also be affected by X-linked disorders due to X-chromosome inactivation, where one X chromosome is silenced in each cell.
Purpose of the Study:
- To explore selective X-chromosome reactivation as a therapeutic strategy for X-linked disorders, particularly Rett syndrome.
- To review current pharmaceutical approaches for restoring MECP2 function in Rett syndrome.
- To discuss the potential of reactivating the inactive X chromosome (Xi) to address the root cause of these disorders.
Main Methods:
- Review of current pharmaceutical pipeline for MECP2 restoration.
- Analysis of selective Xi reactivation methods and their efficacy.
- Discussion of challenges and future directions for Xi reactivation therapies.
Main Results:
- Selective Xi reactivation presents a promising therapeutic avenue by leveraging the healthy gene copy on the inactive X chromosome.
- Existing pharmaceutical approaches focus on restoring MECP2 function for Rett syndrome.
- Further research into Xi reactivation methods is needed to overcome challenges and advance towards clinical application.
Conclusions:
- Selective X-chromosome reactivation is a viable strategy to potentially cure X-linked disorders in females.
- This approach targets the fundamental genetic cause by utilizing the healthy gene on the inactive X chromosome.
- Further development of Xi reactivation techniques is crucial for treating conditions like Rett syndrome.
